Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
LH Form 144 notice reporting a proposed sale of common stock by Fidelity Brokerage Services LLC. The excerpt lists 548 common shares with an aggregate value of $155,999.54, NYSE listing, and a filing date of 02/27/2026.
The entry shows restricted stock vesting activity on 02/07/2025, 02/11/2025, and 02/11/2026 tied to compensation.
LABCORP HOLDINGS INC. executive Brian J. Caveney, EVP and President of Enterprise Diagnostics, Chief Medical Officer and Chief Scientific Officer, reported an open-market sale of common stock. On February 24, 2026, he sold 1,500 shares at an average price of $286.305 per share.
After this transaction, Caveney directly owns 30,106.9234 shares of Labcorp common stock. This filing reflects an insider reducing his direct shareholdings through a routine open-market sale.
Labcorp Holdings Inc. details its 2025 operations, strategy, and risks in its annual report. The company generated $13,951.7 million in revenue, with Diagnostics Laboratories (Dx) contributing $10,876.5 million and Biopharma Laboratory Services (BLS) $3,098.2 million.
Dx focuses on routine and specialty testing, performing more than 750 million tests and serving about 175 million patient encounters through over 2,200 patient service centers and extensive digital tools, including AI‑enabled test selection. BLS supported roughly 85% of FDA drug and therapeutic approvals through global early development and central lab services.
Labcorp invested $582.0 million in acquisitions, spent $434.5 million on capital expenditures (3.1% of revenue) and returned capital via repurchasing 1.8 million shares for $450.0 million and paying $240.7 million in dividends. The report also emphasizes human capital, compliance, AI governance, environmental targets, and extensive regulatory and reimbursement risks.
LH filed a Form 144 reporting proposed sales of common stock tied to restricted stock vesting. The notice lists planned vesting-related dispositions including 458 shares vested 02/06/2025, 447 shares vested 02/07/2025, 66 shares vested 02/11/2025, and 529 shares vested 02/11/2026. The transactions are described as issuer restricted stock vesting.
LABCORP HOLDINGS INC. senior vice president and chief accounting officer Peter J. Wilkinson reported an open-market sale of common stock. On February 19, 2026, he sold 666 shares of Labcorp common stock at a price of $277.94 per share in a transaction coded as an open-market sale. After this sale, he directly owns 1,852.2194 shares of Labcorp common stock. The transaction was executed under a pre-established trading plan adopted in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.
Labcorp Holdings Inc. reported solid growth for 2025 and issued an upbeat 2026 outlook. Revenue rose to $13.95 billion from $13.01 billion, while diluted EPS increased to $10.46 from $8.84 and adjusted EPS climbed to $16.44 from $14.57. Free cash flow improved to $1.21 billion from $1.10 billion.
In the fourth quarter, revenue reached $3.52 billion with adjusted EPS of $4.07, supported by margin expansion in Diagnostics and Biopharma Laboratory Services. For 2026, Labcorp guides to enterprise revenue growth of 4.7%–6.0%, adjusted EPS of $17.55–$18.25, and free cash flow of $1.24–$1.36 billion. The company invested heavily in acquisitions, new specialty tests, and a planned 500,000 square foot central lab facility, while returning cash through $0.72 per-share dividends and $450 million of share repurchases.
Labcorp Holdings Inc. executive Amy B. Summy reported equity compensation activity involving Restricted Stock Units and common stock. On February 11, 2026, 230 Restricted Stock Units were exercised into 230 shares of Labcorp common stock at an exercise price of $0, increasing her directly held common shares to 5,804.5.
On the same date, 83 shares of common stock were automatically withheld at a price of $289.89 per share to cover tax withholding obligations, leaving her with 5,721.5 directly owned shares. The RSUs were part of a grant vesting in three equal annual installments beginning on February 11, 2026, and she held 1,304 Restricted Stock Units after these transactions.
Wilkinson Peter J reported multiple insider transaction types in a Form 4 filing for LH. The filing lists transactions totaling 1,598 shares at a weighted average price of $289.89 per share. Following the reported transactions, holdings were 2,128 shares.
Labcorp Holdings Inc. Chief Financial Officer and EVP Julia Aijun Wang exercised previously granted restricted stock units, receiving 860 shares of common stock on February 11, 2026. Each unit converts into one share of common stock.
To cover tax withholding obligations, 245 shares of common stock were withheld at a price of $289.89 per share. After these transactions, Wang directly holds 1,817.239 shares of common stock and 4,964 restricted stock units, which continue to vest in three equal annual installments beginning February 11, 2026.
Vaughn Bryan T reported multiple insider transaction types in a Form 4 filing for LH. The filing lists transactions totaling 739 shares at a weighted average price of $289.89 per share. Following the reported transactions, holdings were 4,031 shares.